April 19, 2024
A Phase 1 Safety and Efficacy Study of ADI-001 Anti-CD20 CAR-engineered Allogeneic Gamma-Delta (γδ) T Cells in Adults with Refractory B-Cell Malignancies, in Monotherapy and Combination with IL-2
Select an appointment date and time from available spots listed below.